Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is highly aggressive
and hypoxic compared with other subtypes. The role of hypoxia inducible factor 1α (HIF-1α) …

Preoperative bevacizumab and chemotherapy may benefit a subset of breast cancer (BC)
patients. To explore potential mechanisms of this benefit, we conducted a phase II study of …

Anti‐angiogenic therapies have shown limited efficacy in the clinical management of
metastatic disease, including lung metastases. Moreover, the mechanisms via which …

Vessel co-option is a non-angiogenic mechanism of tumour vascularisation in which cancer
cells utilise pre-existing blood vessels instead of inducing new blood vessel formation …

Abstract Background: The anti-angiogenic Sorafenib is the only approved systemic therapy
for advanced hepatocellular carcinoma (HCC). However, acquired resistance limits its …

Angiogenesis research in the past two decades has contributed significantly towards
understanding the molecular pathophysiology of cancer progression and inspired target …

Purpose: Choroidal neovascularization (CNV) is the principal pathological factor
contributing to blindness in neovascular age-related macular degeneration (nAMD) …

Simple Summary The treatment of renal cancer is currently based on the use of
antiangiogenic drugs targeting the VEGF-A pathway and/or immunotherapy targeting …

Agents that target angiogenesis have shown limited efficacy for human triple-negative breast
cancer (TNBC) in clinical trials. Along with endothelium-dependent vessels, there is also …